MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients

Cancers

Iris Schrader¹  Inga Bekes²  Mahdi Rezai³  Georg Heinrich⁴  Matthias W. Beckmann⁵  Hanna Huebner⁵  Naiba Nabieva⁵  Lothar Häberle⁵  Peter A. Fasching⁵  Tanja N. Fehm⁶  Sara Y. Brucker⁷  Brigitte Rack⁸  Visnja Fink⁸  Wolfgang Janni⁸  Fabienne Schochter⁸  Jens-Uwe Blohmer⁹  Volkmar Müller^1,10  Julia Jückstock^1,11  Sven Mahner^1,11  Hans Tesch^1,12  Ralf Lorenz^1,13  Helmut Forstbauer^1,14  Andreas Schneeweiss^1,15 

[1] Breast Center, Diakovere Henriettenstift, 30171 Hannover, Germany;Clinic for Medical Oncology and Hematology, Cantonal Hospital St. Gallen, 9000 St. Gallen, Switzerland;Department of Breast Diseases, Breast Center of Duisburg, Sant Ana Hospitat, 47259 Duisburg, Germany;Department of Gynecologic Oncology, Schwerpunktpraxis für Gynäkologische Onkologie, 40235 Fürstenwalde, Germany;Department of Gynecology and Obstetrics, Comprehensive Cancer Center EMN, Erlangen University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany;Department of Gynecology and Obstetrics, Düsseldorf University Hospital, Heinrich Heine University, 40225 Düsseldorf, Germany;Department of Gynecology and Obstetrics, Tübingen University Hospital, 72076 Tübingen, Germany;Department of Gynecology and Obstetrics, Ulm University Hospital, 89081 Ulm, Germany;Department of Gynecology, Breast Center, Charité-Universitätsmedizin, 10117 Berlin, Germany;Department of Gynecology, University of Hamburg-Eppendorf, 20251 Hamburg, Germany;Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-Universität München (LMU), 80337 Munich, Germany;Department of Oncology, Onkologie Bethanien, 60389 Frankfurt, Germany;Gynecologic Practice Dres Lorenz, Hecker, Wesche, 38100 Braunschweig, Germany;Hemato-Oncological Practice Dres Forstbauer and Ziske, 53840 Troisdorf, Germany;National Center for Tumor Diseases, Heidelberg University Hospital, 69120 Heidelberg, Germany;

关键词: early breast cancer;    tumor marker;    chemotherapy;    anthracycline;    taxane;    MUC1;   

DOI  :  10.3390/cancers14071721

来源: DOAJ

【 摘 要 】

Soluble MUC1 has been discussed as a biomarker for predicting prognosis, treatment efficacy, and monitoring disease activity in breast cancer (BC) patients. Most studies in adjuvant settings have used preoperative assessment. This study, part of the SUCCESS-A trial (NCT02181101), assessed the prognostic value of soluble MUC1 before and after standard adjuvant chemotherapy. Patients with high-risk BC were treated within the SUCCESS-A trial with either three cycles of 5-fluorouracil, epirubicin, and cyclophosphamide followed by three cycles of docetaxel or three cycles of FEC followed by three cycles of docetaxel and gemcitabine. Cox regression analyses were performed to investigate the prognostic value of CA27.29 before and after chemotherapy relative to disease-free survival (DFS), along with established BC prognostic factors such as age, body mass index, tumor size, nodal status, estrogen receptor, progesterone receptor, HER2 status, and grading. Pre-chemotherapy and post-chemotherapy CA27.29 assessments were available for 2687 patients of 3754 randomized patients. Pre-chemotherapy CA27.29 assessment was associated with DFS in addition to established prognostic factors. It had no prognostic value in node-negative patients, but there was a clear association in node-positive patients. Post-chemotherapy CA27.29 assessment did not add any prognostic value, either on its own or in addition to pre-chemotherapy CA27.29 assessment.

【 授权许可】

Unknown